| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
A market of increasing significance Interest in the generic pharmaceutical market continues to grow apace. On the back of the industry s increasingly strong market position - driven by favourable political environments and the number of medicines losing patent protection - industry and investors are re-evaluating the role the generics sector will play in the pharmaceutical industry of the future. For many, the generics market is coming of age. No longer just a peripheral provider of low cost basic medicines, the branded industry, investment community and the generic manufacturers themselves are waking up to the trends which are transforming the generics sector, and the increasingly important role emerging markets are playing in it. Key company analysisThat is why Espicom, publisher of the respected monthly business publication World Generic Markets, has launched a completely new service called Generic Companies Analysis (GCA). Packed with facts, figures and statistics, this service provides the most thorough ongoing monitoring of the important generic companies. From financial performance to litigation, no other service provides such insight to the companies driving growth in this rapidly expanding area of the pharmaceutical industry. GCA: published quarterly to keep you in touchGCA company reports are updated and issued every quarter. This ongoing monitoring and regular delivery ensures that developments are incorporated into the relevant reports. This vigilance ensures that whether its the latest deals, ANDAs, alliances or litigation you can assess the impact of the development in the context of the company, its competitors and the broader market. Formats to suit every needGCA Web Instant access 24/7 to the latest content on the companies covered. With GCA Web you get the current quarterly issued information and a host of useful features, such as "Search", to quickly find the information you need. GCA Print The traditional service featuring a loose-leaf binder in which you can store your printed company reports. Each quarter you will receive all new/updated company reports that can be easily filed. Unbeatable Quarterly-Updated Content- Executive commentary Easy to read snapshots of the company highlights
- Financial performance The most recent quarterly and annual financial results. Comparative figures, charts and a detailed review of the data allow you to track a company s progress
- Products A review of the company s active products line up, with regular updates on new products, approvals and launches - all put into their competitive context.
- ANDAs ANDAs in the all important US generic market are listed by company each quarter
- Major developments M&A activity and strategic alliances and Litigation. Fully understand the dynamic and complex issues affecting the business of leading generic industry players.
So you don t need Generic Companies Analysis?"We can do this ourselves" Possibly, but at what cost in terms of time and effort? Executive time spent on research is not time well spent when current information is available immediately from GCA. "This information is in our Library/Information Centre" Some information is very likely to be there, but unless, as with GCA, there is a team of analysts and researchers compiling and updating the information full time, internal sources are unlikely to be as comprehensive or up-to-date as GCA. "We can get all this information off the Internet" If only that were true! Some sources of information on the Internet are trustworthy, others not. Data is not always updated, and one must be ever cautious. GCA editors and analysts directly contact key information sources in industry, commerce, government and trade associations to compile GCA. Much of that information is not easily accessible in the public domain. Leading companies covered- Alpharma
- Andrx Corporation
- Apotex
- Aspen Pharmacare
- Barr Laboratories
- CIPLA
- Dr Reddy s
- EGIS
- EON Labs
- Hexal AG
- IVAX Corp
- KRKA
- Lannett
- Lek
- Merck Generics
- Mylan Labs
- Perrigo
- Pliva
- Ranbaxy
- ratiopharm
- Gedeon Richter
- Sandoz
- Sawai
- Stada Arzneimittel
- Teva Pharmaceutical Industries
- Watson Pharmaceuticals
- Zentiva
- Zydus Cadila
TABLE OF CONTENTS
Ranbaxy Laboratories- EXECUTIVE SUMMARY.
- INTRODUCTION
- Subsidiaries of Ranbaxy, 2004
- PRODUCTS
- International Regulatory Findings and Approvals, January - December 2003
- Anda Approvals, 2003-2004.
- Top 10 selling Ranbaxy products
- Global markets
- FINANCIAL RESULTS
- Latest Yearly Results
- Financial results 2000-2003 (Rs, millions)
- Financial Results, 1996-2003, (Rs, million)
- Breakdown of expenses, 2003
- Latest Quarterly Results
- Ranbaxy Laboratories: second quarter 2004 results
- Ranbaxy Laboratories: second quarter 2004 revenue breakdown
- Ranbaxy Laboratories: mid-year 2004 results
- Ranbaxy Laboratories: mid-year 2004 revenue breakdown
- MAJOR DEVELOPMENTS
- Mergers, acquisitions and agreements
- CONTACT DETAILS
|
